Omalizumab for chronic spontaneous utricaria: predicted versus actual analysis
Page last updated: 1 September 2023
Drug utilisation sub-committee (DUSC)
June 2020
Abstract
Purpose
To compare the predicted and actual utilisation of omalizumab for severe chronic spontaneous urticaria (CSU) since it was PBS listed for this indication.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Omalizimuab was first listed on the PBS for severe chronic spontaneous urticaria on
1 September 2017.
Data Source / methodology
Authorities data and prescriptions data was extracted from the Services Australia prescription database and Authorities database from 1 September 2017, respectively. Data were extracted based on the date of supply.
Key Findings
- The number of patients supplied omalizumab for CSU was more than predicted in its first two years of listing. In Year 2 of listing, a total of 2,206 patients were supplied omalizumab.
- The proportion of patients continuing on omalizumab was less than anticipated and the number of packs per patient was lower than predicted.
- Only a small proportion of patients (2%) were identified as having their dose down-titrated from 300 mg to 150 mg.
